The effect of EMPAgliflozin on markers of inflammation in patients with concomitant type 2 diabetes mellitus and Coronary ARtery Disease: the EMPA-CARD randomized controlled trial
Sepehr Gohari, Tara Reshadmanesh, H. Khodabandehloo, Amir Karbalaee-Hasani +16 more

